Ovid Therapeutics Inc (OVID) Stock Price, Quote & News

Company Profile

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and pediatric drug-resistant epilepsies; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It...

Industry: Biotechnology

Sector: Healthcare

Phone: 646 661 7661

Fax: 646 661 4027

Website: www.ovidrx.com

Address:

441 Ninth Avenue, 14th Floor, New York, United States

Doom_Gloom_AR Nov. 15 at 4:49 AM

$OVID hi ovidians, I have a small tracking position, waiting on the kcc2. Could be a blockbuster and I know I'm too early.

0 · Reply

lucabrix Nov. 14 at 4:37 PM

$OVID Reply!

0 · Reply

hatka Nov. 14 at 4:22 PM

$OVID

0 · Reply

don_111 Nov. 13 at 3:11 PM

$OVID Long - buying these dips

1 · Reply

Tonydarien Nov. 13 at 3:14 AM

$OVID https://www.moomoo.com/news/post/61400433?ns_stock_id=74225625022636&main_broker=WwogIDEwMDcKXQ==&skintype=3&src=2&us_cid=72749871&futusource=news_stock_stockpagenews&client_hour_clock=24&level=1&global_content=%7B%22promote_content%22%3A%22mm%3Apost%3A61400433%22%2C%22invite%22%3A72749871%7D&data_ticket=f95e6a1060e5164f39bed19899bf0956

0 · Reply

Tonydarien Nov. 13 at 3:14 AM

$OVID https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-63?utm_source=moomoo.com&utm_medium=referral

0 · Reply

REDWIR Nov. 12 at 7:34 PM

$OVID It was just 1.24 the other day it didn’t even get to that after missed earnings . Yeah yeah ceo is stepping down but he built the greatest pipeline we could ask for. Multiple drugs on phase 2 and once they get approved that’s when this stock 10x.

1 · Reply

d_risk Nov. 12 at 4:24 PM

$OVID - Ovid Therapeutics Inc. Common Stock - 10Q - Updated Risk Factors OVID’s latest 10-Q risk factors spotlight urgent capital needs, high costs and delays in drug development, new limits on capital raising, expanded compliance and reimbursement risks, increased reliance on third parties, cybersecurity threats, Nasdaq delisting risk, and heightened exposure to litigation and anti-takeover provisions. #Biotechnology #RegulatoryCompliance #Cybersecurity #CapitalRisk #DrugDevelopment 🟢 Added 🟠 Removed https://d-risk.ai/OVID/10-Q/2025-11-12

0 · Reply

Tonydarien Nov. 12 at 3:45 PM

$OVID Ten years after founding Ovid Therapeutics, CEO Jeremy Levin plans to step down and hand over the top spot to COO Meg Alexander. Alexander will formally take the reins at the beginning of next year, the company told Endpoints News. Levin will lead the board as executive chairman.4 hours ago

0 · Reply

SannieVerraderlijk Nov. 12 at 2:37 PM

$OVID Added the Meg dip

0 · Reply

Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results

Oct 3, 2025, 12:52 PM EDT - 6 weeks ago

Ovid Therapeutics Inc. - Special Call

Oct 3, 2025, 7:05 AM EDT - 6 weeks ago

Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds

Oct 3, 2025, 7:00 AM EDT - 6 weeks ago

Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile

Aug 13, 2025, 8:00 AM EDT - 3 months ago

Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results

Jul 23, 2025, 8:30 AM EDT - 4 months ago

Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference

Jun 25, 2025, 8:00 AM EDT - 5 months ago

Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties

May 13, 2025, 8:00 AM EDT - 6 months ago

Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results

Mar 11, 2025, 8:00 AM EDT - 8 months ago

Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Mar 3, 2025, 8:00 AM EST - 9 months ago

Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors

Feb 27, 2025, 8:00 AM EST - 9 months ago

Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Feb 5, 2025, 8:00 AM EST - 10 months ago

Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Sep 11, 2024, 8:00 AM EDT - 1 year ago

Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth

Aug 19, 2024, 11:00 AM EDT - 1 year ago

Shareholders In Ovid Therapeutics Inc Invited To Participate In Fraud Investigation With The Schall Law Firm

Aug 18, 2024, 11:00 AM EDT - 1 year ago

Ovid Therapeutics Inc Investors Encouraged To Join Fraud Investigation With Schall Law Firm

Aug 17, 2024, 11:00 AM EDT - 1 year ago

Ovid Therapeutics Inc Shareholders Eligible To Participate In Fraud Investigation With Schall Law Firm

Aug 16, 2024, 11:00 AM EDT - 1 year ago

Ovid Therapeutics Inc Investors Invited To Join In Fraud Investigation With Schall Law Firm

Aug 15, 2024, 11:00 AM EDT - 1 year ago

Ovid Therapeutics Inc Shareholders Encouraged To Join Fraud Investigation With Schall Law Firm

Aug 14, 2024, 10:30 PM EDT - 1 year ago

Ovid Therapeutics Inc Shareholders Invited To Join Fraud Investigation With Schall Law Firm

Aug 14, 2024, 1:15 AM EDT - 1 year ago

Ovid Therapeutics Inc Investors Welcome To Participate In Fraud Investigation With Schall Law Firm

Aug 13, 2024, 8:00 AM EDT - 1 year ago

Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results

Aug 12, 2024, 11:55 PM EDT - 1 year ago

Ovid Therapeutics Inc Investors Invited To Join Fraud Investigation With Schall Law Firm

Aug 9, 2024, 9:15 PM EDT - 1 year ago

Investors Of Ovid Therapeutics Inc Can Participate In Fraud Investigation With The Schall Law Firm

Aug 8, 2024, 4:00 PM EDT - 1 year ago

Investors Of Ovid Therapeutics Inc Eligible To Join Fraud Investigation With The Schall Law Firm

Aug 7, 2024, 11:30 PM EDT - 1 year ago

Investors Of Ovid Therapeutics Inc Can Join Fraud Investigation With The Schall Law Firm

Aug 6, 2024, 4:00 PM EDT - 1 year ago

Ovid Therapeutics Inc Investors Can Participate In Fraud Investigation With The Schall Law Firm

Aug 2, 2024, 10:00 AM EDT - 1 year ago

OVID Investors Have Opportunity to Join Ovid Therapeutics Inc. Fraud Investigation with the Schall Law Firm

Jul 30, 2024, 8:00 AM EDT - 1 year ago

Ovid Therapeutics to Present at Upcoming August Investor Conferences

Jul 23, 2024, 8:00 AM EDT - 1 year ago

Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists

Jul 1, 2024, 8:00 AM EDT - 1 year ago

Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations

Jun 17, 2024, 8:58 AM EDT - 1 year ago

What's Going On With Ovid Therapeutics After Takeda's Two Phase 3 Epilepsy Studies Fail?

TAK

Jun 17, 2024, 6:55 AM EDT - 1 year ago

Ovid Therapeutics Reports on Takeda's Announcement of Phase 3 Topline Study Results for Soticlestat

May 14, 2024, 8:00 AM EDT - 1 year ago

Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results

May 13, 2024, 7:00 AM EDT - 1 year ago

Ovid Therapeutics to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference

Apr 9, 2024, 10:48 AM EDT - 1 year ago

Ovid Therapeutics: Data Readouts For Rare Epileptic Indications Late 2024

Apr 4, 2024, 8:00 AM EDT - 1 year ago

Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

Mar 8, 2024, 8:00 AM EST - 1 year ago

Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results

Feb 28, 2024, 8:00 AM EST - 1 year ago

Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference

Feb 6, 2024, 8:00 AM EST - 1 year ago

Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Dec 1, 2023, 7:30 AM EST - 2 years ago

Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023)

Nov 3, 2023, 8:00 AM EDT - 2 years ago

Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates

Oct 18, 2023, 8:00 AM EDT - 2 years ago

Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid's Cash Runway into 2026

Oct 10, 2023, 8:00 AM EDT - 2 years ago

Ovid Therapeutics to Present at the Jefferies Biotech CNS/Neuro Summit

Sep 26, 2023, 7:30 AM EDT - 2 years ago

Ovid Therapeutics to Host Investor Event - R&D Day on Monday, October 2, 2023

Sep 20, 2023, 7:30 AM EDT - 2 years ago

Ovid Therapeutics to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference

Doom_Gloom_AR Nov. 15 at 4:49 AM

$OVID hi ovidians, I have a small tracking position, waiting on the kcc2. Could be a blockbuster and I know I'm too early.

0 · Reply

lucabrix Nov. 14 at 4:37 PM

$OVID Reply!

0 · Reply

hatka Nov. 14 at 4:22 PM

$OVID

0 · Reply

don_111 Nov. 13 at 3:11 PM

$OVID Long - buying these dips

1 · Reply

Tonydarien Nov. 13 at 3:14 AM

0 · Reply

Tonydarien Nov. 13 at 3:14 AM

$OVID https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-63?utm_source=moomoo.com&utm_medium=referral

0 · Reply

REDWIR Nov. 12 at 7:34 PM

1 · Reply

d_risk Nov. 12 at 4:24 PM

0 · Reply

Tonydarien Nov. 12 at 3:45 PM

0 · Reply

SannieVerraderlijk Nov. 12 at 2:37 PM

$OVID Added the Meg dip

0 · Reply

BiodegradableBurger Nov. 12 at 2:25 PM

$OVID It is a planned succession and we down 10%?

0 · Reply

tttggg Nov. 12 at 1:38 PM

$OVID why is Levin stepping down as CEO???

1 · Reply

SofaKing_Nuts Nov. 12 at 12:52 PM

$OVID 10-Q is filed. FUDsters will probably run this down a little more. good opportunity to reload some cheapies

0 · Reply

DARKP00L Nov. 12 at 12:26 PM

$OVID 07:07 on Nov. 12 2025 Ovid Therapeutics Names Meg Alexander CEO, Effective January 1, 2026; Appoints Dr. Jeremy Levin As Executive Chair Of The Board #tradeideas

0 · Reply

holmyown01 Nov. 11 at 1:08 PM

$OVID thought earnings was this morning

1 · Reply

REDWIR Nov. 10 at 5:32 PM

$RDW meet $OVID my two biggest bag holders. Would love a partnership just manifesting 😊

0 · Reply

Achouffe Nov. 10 at 11:54 AM

$SLS $LXRX $OVID $ATOS $IOVA My small biotech portfolio. Pls help me improve. Constructive input appreciated.

8 · Reply

Lovelylatta Nov. 7 at 10:54 PM

$OVID I voted no 🙂‍↔️

1 · Reply

REDWIR Nov. 7 at 9:51 PM

$OVID holding 1 year line perfectly

0 · Reply

Tonydarien Nov. 7 at 9:13 PM

$OVID excellent recovery. December & February milestones are key to upward movement.

1 · Reply

REDWIR Nov. 7 at 3:46 PM

$OVID legitimately no reason this is going down 10 percent in 2 days.

0 · Reply

BiodegradableBurger Nov. 7 at 2:49 PM

$OVID Psychotic stock. Yesterday we hit $1.42, today $1.28.

0 · Reply

Market Cap	85.33M
Revenue (ttm)	570,000.00
Net Income (ttm)	-26.43M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-4,636.84%
Debt to Equity Ratio	0.00

Volume	1,098,300
Avg Vol	3,138,732
Day's Range	N/A - N/A
Shares Out	71.11M
Stochastic %K	49%
Beta	0.32
Analysts	Strong Sell
Price Target	$4.50